Latest Convertible Notes News

Elevra Lithium’s North American Lithium operation hit a new monthly spodumene concentrate production record in May 2026 while closing a US$298 million financing package to fund expansion and project development.

Lion Energy has locked in funding and government approval for its Bula Karang-1 well in Indonesia, targeting a September spud, while winding down its hydrogen project to focus on core upstream oil and gas activities.

The Calmer Co International Ltd is raising up to $3.5 million through a 1-for-1 renounceable entitlement offer priced at $0.001 per share, including free attaching options exercisable at $0.002. The capital will fund debt repayment, inventory expansion, marketing, and product launches.

Lotus Resources has secured A$34.2 million from institutional investors in a fully underwritten entitlement offer, with a retail component set to raise an additional A$26 million. The funds aim to support the Kayelekera uranium project’s production ramp-up and financial stability.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

Aldoro Resources has solidified its position in critical minerals with a major resource update at Kameelburg, revealing the world’s largest Strontium deposit alongside high-grade rare earth and niobium mineralisation, backed by robust Phase II drilling and metallurgical advances.

Highfield Resources has obtained a fourth tranche of A$700,000 under its Convertible Note Facility despite a legal event releasing noteholders from future funding obligations. The company continues its Supreme Court appeal and funding discussions to advance the Muga Potash Project.

Complii FinTech Solutions reported modest ARR growth and a key institutional contract in Q4 FY26, while advancing product development and managing cash flow pressures.

Global Health Limited boosted customer receipts by 12.6% to A$9.53 million for FY26, completing its SaaS platform upgrade and cutting cash burn by 30%. The company targets sustained EBITDA profitability and international expansion in FY27.

Paradigm Biopharmaceuticals has strengthened its balance sheet with a combined $5.75 million cash inflow from Australian Government R&D tax incentives, supporting its pivotal Phase 3 osteoarthritis trial and regulatory efforts.

Noumi Limited has struck a binding deal with major shareholder Arrovest to acquire all remaining shares via a scheme of arrangement, offering shareholders a 12.2% premium amid looming $610 million convertible note maturity.

Aldoro Resources has secured A$4.3 million through unsecured convertible notes, providing funding to accelerate development at its Kameelburg Critical Minerals Project and exploring a potential Hong Kong Stock Exchange listing.